Teduglutide est glucagona quasi peptide-2 (GLP-2) analogon. Hoc ex 33 amino acida et fabricatur per contentionem colium Escherichiae a recombinante DNA technologiae accommodatum. Teduglutide differt a GLP-2 uno amino acido (alanine substituitur glycine). Significatio huius substitutionis est quod teduglutides longiorem agentes quam endogenous GLP-2 sicut proteolysi a dipeptidylo peptidase-4 magis repugnant.. FDA approved on December 21, 2012.
Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine in response to meals. GLP-2 increases intestinal and portal blood flow and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. This causes the release of insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF). These growth factors may contribute to the increase in crypt cell growth and surface area of the gastric mucosa. Ultimo, absorption through the intestine is enhanced.
